Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Adjuvant chemotherapy improves survival in early-stage ovarian cancer

15.01.2003


Results from two large European studies suggest that adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer can increase some patients’ chances of both overall and recurrence-free survival. The findings are reported in three articles in the January 15 issue of the Journal of the National Cancer Institute.



As many as 50% of patients with early-stage ovarian cancer relapse after surgery, and these subsequent tumor recurrences are often resistant to treatment. Adjuvant chemotherapy has been used to prevent recurrence; however, definitive data are lacking on the effectiveness of adjuvant therapy, and there is no information available about which patients may benefit the most. In addition, previous trials have been too small to provide clear answers.

In the early 1990s, two large randomized clinical trials were initiated to compare survival between patients treated with adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer and patients who received no additional treatments until clinically indicated.


In the Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION) trial, a team of researchers from the European Organisation for Research and Treatment of Cancer (EORTC) randomly assigned 448 patients from across Europe to either adjuvant platinum-based chemotherapy or observation following surgery. This trial also examined the impact of completeness of surgical staging on survival. One-third of the patents received optimal surgical staging for their cancers. This meant that clinicians performed all the requirements to determine the extent of the disease, or its stage. The remaining two-thirds of patients received nonoptimal surgical staging.

At 5 years, there was no statistically significant difference in overall survival between patients who were treated with adjuvant chemotherapy and patients who were in the observation group. However, recurrence-free survival was statistically significantly improved, with 76% of patients treated with adjuvant chemotherapy surviving without a recurrence, compared with 68% of patients in the observation arm.

Moreover, the authors found that among patients who did not receive adjuvant chemotherapy, optimal staging was associated with a statistically significant improvement in overall and recurrence-free survival. In contrast, optimal staging was not associated with any survival benefit in patients who received adjuvant chemotherapy. Adjuvant chemotherapy appeared to only benefit patients whose cancers were not optimally staged.

"This finding suggests that adjuvant chemotherapy in early-stage ovarian cancer may work predominantly by affecting small-volume or microscopic tumor implants or metastases that remain unnoticed at the time of surgical staging," the authors write. They add that the observed benefit of adjuvant chemotherapy primarily in nonoptimally staged patients suggests a benefit of adjuvant chemotherapy predominantly in patients with unrecognized residual disease.

In a second trial, the International Collaborative Ovarian Neoplasm (ICON1) study, collaborators randomly assigned 477 patients to receive either adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer or no immediate adjuvant chemotherapy. (Information on the completeness of surgical staging was not collected in this trial.)

At 5 years, women who received adjuvant chemotherapy had a 9% greater overall survival and an 11% greater recurrence-free survival than women who did not receive immediate adjuvant therapy.

In a separate paper, researchers reported findings from a combined analysis of the two trials. Similar to the ICON1 trial, the combined analysis found that 5-year overall survival was 8% greater in the adjuvant chemotherapy arm than in the observation arm. The analysis also found that 5-year recurrence-free survival was 11% better in the adjuvant chemotherapy arm than in the observation arm.

In an accompanying editorial, Robert C. Young, M.D., of the Fox Chase Cancer Center in Philadelphia, says that the trials add important information on adjuvant chemotherapy but do not address which patients can be spared unnecessary adjuvant chemotherapy.

He recommends that future trials focus on identifying patients who do not require additional therapy while also seeking to improve therapy in patients who do. "Selecting only high-risk patients for additional treatment can narrow the use of chemotherapy, and this approach should be used until such time as a randomized trial can demonstrate that good prognosis, early-stage patients benefit from such therapy," he writes.


Contact: Dr. J. Baptist Trimbos, Leiden University Medical Center, Netherlands, 31-71-526-2845, J.B.M.Z.Trimbos@lumc.nl

Dr. David Guthrie, Derbyshire Royal Infirmary, 44-122-852-3444, DGJCGuthrie@aol.com

Editorial: Karen Carter Mallet, Fox Chase Cancer Center, 215-728-2700; fax: 215-728-2594, k_carter@fccc.edu

International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105–112.

Trimbos J, Vergote I, Bolis G, Vermorken J, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003;95:113–25.

International Collaborative Ovarian Neoplasm Trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003;95:125–32.

Editorial: Young R. Early-stage ovarian cancer: To treat or not to treat. J Natl Cancer Inst 2003;95:94–5.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Linda Wang | EurekAlert!
Further information:
http://jncicancerspectrum.oupjournals.org/

More articles from Health and Medicine:

nachricht Custom-tailored strategy against glioblastomas
26.09.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New welding process joins dissimilar sheets better

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of light metals.
Scientists at the University of Stuttgart have now developed two new process variants that will considerably expand the areas of application for friction stir welding.
Technologie-Lizenz-Büro (TLB) GmbH supports the University of Stuttgart in patenting and marketing its innovations.

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of...

Im Focus: First quantum photonic circuit with electrically driven light source

Optical quantum computers can revolutionize computer technology. A team of researchers led by scientists from Münster University and KIT now succeeded in putting a quantum optical experimental set-up onto a chip. In doing so, they have met one of the requirements for making it possible to use photonic circuits for optical quantum computers.

Optical quantum computers are what people are pinning their hopes on for tomorrow’s computer technology – whether for tap-proof data encryption, ultrafast...

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

HLF: From an experiment to an establishment

29.09.2016 | Event News

European Health Forum Gastein 2016 kicks off today

28.09.2016 | Event News

Laser use for neurosurgery and biofabrication - LaserForum 2016 focuses on medical technology

27.09.2016 | Event News

 
Latest News

New Multiferroic Materials from Building Blocks

29.09.2016 | Materials Sciences

Silicon Fluorescent Material Developed Enabling Observations under a Bright “Biological Optical Window”

29.09.2016 | Materials Sciences

X-shape Bio-inspired Structures

29.09.2016 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>